DNLI has had a good run in the past year on positive pipeline updates. A potential approval of its Hunter Syndrome drug should be a boost. However, recent pipeline setbacks warrant caution.

Denali Therapeutics DNLI has performed well in the past 12 months amid a volatile market. Shares of the company have gained 26.6% against the industry’s decline of 14.3%. The stock has also ...

Analyst Thomas Shrader from BTIG maintained a Buy rating on Denali Therapeutics (DNLI – Research Report) and keeping the price target at $32.00. Thomas Shrader’s rating is based on Denali ...

Riad Sattouf’s saga of his parents’ failed bicultural marriage, with its harsh depiction of life in rural Syria, has become a literary sensation. By Richard Fausset A popular TV host ...

The Walt Disney Company operates as an entertainment company worldwide. It operates through three segments: Entertainment, Sports, and Experiences. The company produces and distributes film and ...

Hundreds of truckloads of food, fuel and other supplies have arrived in Gaza each day since the cease-fire took effect. But the need is vast after 15 months of war. By Vivian Yee and Bilal ...

Jan. 22, 2025 — Pathogen-fighting immune cells called tissue-resident memory CD8 T cells (TRM cells) go through a surprising transformation -- and relocation -- as they fight infections in the ...